Table 2. Changes in gene regulation in E19 placenta following maternal treatment with paracetamol.
| E19 Placenta: immune/inflammation-related genes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Up-regulated (chronic/control) | Up-regulated (acute/control) | |||||||||
| ID | Gene | Ch /
Co |
Ac /
Co |
Ch /
Ac |
ID | Gene | Ch /
Co |
Ac /
Co |
Ch /
Ac |
|
| NM_013025 | Ccl3 | 42 | - | 34 | NM_013095 | Smad3 | - | 1.61 | - | |
| NM_053647 | Cxcl2 | 23 | - | 17 | NM_001025721 | Colec12 | - | 1.59 | - | |
| NM_031512 | Il1b | 13 | - | 17 | NM_001008328 | Parp3 | - | 1.50 | - | |
| NM_022194 | Il1rn | 7.75 | - | 6.19 | NM_017113 | Grn | - | 1.48 | - | |
| NM_130741 | Lcn2 | 3.89 | - | 3.91 | NM_133380 | Il4r | - | 1.46 | 0.78 | |
| NM_001131001 | Fcer1g | 3.20 | - | 3.60 | NM_031514 | Jak2 | - | 1.35 | - | |
| NM_024145 | Fgr | 2.87 | - | 2.17 | NM_173328 | Lgr4 | - | 1.32 | - | |
| NM_012711 | Itgam | 2.86 | - | 2.92 | NM_001107754 | Traf6 | - | 1.31 | - | |
| NM_021744 | Cd14 | 2.71 | - | - | NM_001107063 | Cdc42ep4 | - | 1.28 | - | |
| NM_130426 | Tnfrsf1b | 2.51 | - | 1.89 | NM_001191552 | Nsd2 | - | 1.24 | - | |
| NM_053822 | S100a8 | 2.26 | - | 4.72 | NM_001017385 | Kdelr1 | - | 1.22 | - | |
| NM_030845 | Cxcl1 | 2.21 | - | - | NM_012925 | Cd59 | - | 1.21 | - | |
| NM_001031642 | Serpinb1a | 2.17 | - | 1.68 | NM_001106715 | Pum2 | - | 1.19 | - | |
| NM_001008384 | Rac2 | 2.07 | - | 2.83 | ||||||
| NM_001009681 | Oasl | 1.95 | - | - | ||||||
| NM_001009689 | Cdc42ep2 | 1.79 | - | - | ||||||
| NM_001134555 | C1r | 1.71 | - | - | ||||||
| NM_012673 | Thy1 | 1.66 | - | - | ||||||
| NM_001136124 | Ifitm3 | 1.56 | - | - | ||||||
| NM_001013062 | Thbs1 | 1.55 | - | - | ||||||
| NM_001106314 | Ifitm1 | 1.52 | - | - | ||||||
| NM_053535 | Enpp1 | 1.47 | - | - | ||||||
| NM_138881 | Rsad2 | 1.45 | - | - | ||||||
| NM_138844 | Unc13d | 1.44 | - | - | ||||||
| NM_013016 | Sirpa | 1.43 | - | - | ||||||
| NM_001166403 | RT1-T24-3 | 1.43 | - | - | ||||||
| NM_001191760 | Dock11 | 1.37 | - | 1.24 | ||||||
| NM_001271227 | Tfe3 | 1.36 | - | - | ||||||
| NM_001100565 | Peli1 | 1.31 | - | - | ||||||
| NM_001108101 | Irak3 | 1.30 | - | 1.33 | ||||||
| NM_023092 | Myo1c | 1.30 | - | - | ||||||
| NM_031140 | Vim | 1.30 | - | - | ||||||
| NM_017256 | Tgfbr3 | 1.26 | - | - | ||||||
| NM_133624 | Gbp2 | 1.91 | - | 1.86 | ||||||
| NM_021655 | Chga | 1.70 | - | 1.71 | ||||||
| NM_013069 | Cd74 | 1.61 | - | 1.79 | ||||||
| Down-regulated (chronic/control) | Down-regulated (acute/control) | |||||||||
| ID | Gene | Ch / Co | Ac / Co | Ch / Ac | ID | Gene | Ch / Co | Ac / Co | Ch / Ac | |
| NM_020071 | Fgb | -639 | - | - | NM_001109535 | Rab20 | - | -1.93 | 1.89 | |
| NM_013112 | Apoa2 | -474 | - | - | NM_001108207 | Tnfrsf21 | - | -1.75 | - | |
| NM_001007729 | Cxcl4 | -1.55 | - | - | NM_053587 | S100a9 | 2.16 | -1.71 | 3.70 | |
| NM_001106095 | Lig4 | -1.53 | - | - | NM_173838 | Fzd5 | - | -1.53 | - | |
| NM_001008322 | Shmt2 | -1.46 | - | - | NM_001025707 | Tfeb | - | -1.40 | - | |
| NM_030826 | Gpx1 | -1.39 | - | - | NM_012939 | Ctsh | - | -1.40 | - | |
| NM_001108741 | Appl2 | -1.26 | - | - | NM_001025672 | Pspc1 | - | -1.34 | - | |
| NM_001127390 | Washc1 | -1.25 | - | - | NM_013157 | Ass1 | - | -1.34 | - | |
| NM_001108069 | Stk11 | -1.23 | - | - | NM_001031653 | Polr3d | - | -1.23 | - | |
| NM_001134974 | Trim27 | -1.20 | - | - | NM_001024967 | Tmem106a | - | -1.23 | - | |
| NM_019357 | Ezr | - | -1.22 | - | ||||||
| NM_053743 | Cdc37 | - | -1.18 | - | ||||||
Up-regulated and down-regulated inflammatory and immune-related gene changes in E19 placenta following no treatment (co, controls), acute (ac,) or chronic (ch) maternal paracetamol treatment; see Methods for details of dosage schedule. Data from RNA-Seq analysis. Numbers are fold changes for comparisons indicated (Ch/Co, Ac/Co, Ch/Ac). The chronic/acute comparison indicates significant differences in regulation between the two dosage regimes (P<0.05, see Methods). In all cases expression was greater with chronic treatment. This table includes only genes with inflammatory and immune-related functions and thus includes some of the highly expressed genes in Table 1.